A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI

BPH Clinical Trial

Official title:

A Pilot and Prospective Study to Observe the Mechanism of Action of Medi-Tate i-Temporary Implantable Nitinol Device (iTind) in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH) With Magnetic Resonance Imaging (MRI)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03994263
• Other study ID #: MT-09
• Status: Terminated
• Phase: N/A
• Start date: November 18, 2019
• Est. completion date: February 18, 2021

Study information

• Verified date: September 2021
• Source: Medi-Tate Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A total of up to 15 eligible subjects will be enrolled into this open-labeled one-arm study designed to observe the mechanism of action of iTind when using MRI

Description:

Study Objective:

To validate the iTind efficacy by using MRI in subjects with symptomatic BPH. Specifically the pressure points created by the iTind's struts and its implications on blood flow to the prostate will be assessed.

Efficacy Endpoints:

The endpoints of this study are:

• Decrease in transition zone volume

• Monitor size and location of ablative lesions

• Monitor change in time of lesions

• Monitor the correspondence change in prostate tissue All the above will be assessed by using MRI.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: February 18, 2021
• Est. primary completion date: February 18, 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Subject signed informed consent form (ICF)

• Age 40 and above- Male with symptomatic BPH.

• IPSS symptom severity score = 13

• Peak urinary flow of < 12 ml/sec

• Prostate volume between 25 ml to 80 ml (assessed by pre-operative ultrasound - TRUS)

• Blood CBC and biochemistry up to two weeks before screening, demonstrating: Normal values of the PT, PTT and INR tests (Anticoagulants washout may be done two weeks prior of device implantation)

• Subject able to comply with the study protocol

• Normal urinalysis and negative urine culture

• Subjects that are able to undergo MRI.

Exclusion Criteria:

• A post void residual (PVR) volume > 250 ml measured by ultrasound or acute urinary retention

• Confirmed or suspected bladder cancer;

• Recent (within 3 months) cystolithiasis or hematuria;

• Urethral strictures, bladder neck contracture, urinary bladder stones or other potentially confounding bladder pathology;

• An active urinary tract infection.

• Enrolled in another treatment trial for any disease within the past 30 days.

• Previous colo- rectal surgery (other than hemorrhoidectomy) or history of rectal disease if the therapy may potentially cause injury to sites of previous rectal surgery, e.g., if a transrectal probe is used;

• Previous pelvic irradiation, cryosurgery or radical pelvic surgery;

• Previous prostate surgery, balloon dilatation, stent implantation, laser prostatectomy, hyperthermia, or any other invasive treatment to the prostate

• Median lobe obstruction of the prostate (larger than 1cm).

• Cancer that is not considered cured, except basal cell or squamous cell carcinoma of the skin (cured defined as no evidence of cancer within the past 5 years)

• Patient with renal dysfunction

• Any serious medical condition likely to impede successful completion of the study

Related Conditions & MeSH terms

• BPH

Intervention

Device:
• ITind device implant
device implanted for 5-7 days

Locations

Country	Name	City	State
Germany	Kliniken Nordoberpfalz AG Klinik für Urologie, Kinderurologie und interdisziplinäres Prostatakarzinomzentrum	Weiden

Sponsors (1)

Lead Sponsor	Collaborator
Medi-Tate Ltd.

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AE rate	Incidence (% of subjects) and frequency (no. of events) of device related adverse events.	12 months
Primary	Unexpected SAE	Incidence (% of subjects) and frequency (no. of events) of unexpected serious adverse events deemed as related to Meditate iTIND and/or to implantation/retrieval procedures.	12 months
Primary	Device complications	Incidence (% of subjects) and frequency (no. of events) of Meditate iTIND and/or to implantation/retrieval procedures complications	12 months